LKFT
Lakefront Biotherapeutics NV
Set alert
- YTD
- -1.28%
- 1 year
- +3.00%
- Open
- 32.42
- Prev close
- 32.33
- Mkt cap
- 2.13B
- Vol
- 164.06K
- Avg vol
- 285.76K
- EPS
- 10.52
- P/E
- 3.07
- Div yield
- 0.00%
More statistics
- Low
- 32.06
- High
- 32.76
- Forward P/E
- -27.11
- Beta
- 0.06
- Short ratio
- 3.95
- Inst. own
- 23.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 29.41
- 200-d avg
- 29.93
- 1y target
- 30.34
Key statistics
- Market cap
- 2.13B
- Enterprise value
- 40.22B
- Trailing P/E
- 3.07
- Forward P/E
- -27.11
- PEG ratio
- 0.00
- Price / sales
- 2.15
- Price / book
- 11.56
- EPS (TTM)
- 10.52
- Beta
- 0.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 60.23%
- Revenue (TTM)
- 990.57M
- Revenue growth
- -81.50%
- Free cash flow
- 138.21M
- Total cash
- 2.24B
- Total debt
- 6.36M
- Return on equity
- 20.12%
- Shares outstanding
- 65.90M
- Short % of float
- 3.50%
- 50-day average
- 29.41
- 200-day average
- 29.93
Analyst view
Consensus: hold
- Target (low)
- 21.22
- Target (mean)
- 30.34
- Target (high)
- 43.92
- Strong buy1
- Buy1
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.83178 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.82265 | 0.03448 | +0.86 | +104.19% |
| May 6, 2026 | Mar 31, 2026 | -0.94363 | 0.2473 | +1.19 | +126.21% |
| Feb 23, 2026 | Dec 31, 2025 | -0.12662 | 13.90 | +14.03 | +11,077.73% |
| Nov 5, 2025 | Sep 30, 2025 | -0.47781 | -3.54 | -3.06 | -641.43% |
| Jul 23, 2025 | Jun 30, 2025 | -0.22826 | -1.85 | -1.62 | -711.81% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | RBC Capital | up | Sector Perform | Outperform |
| Aug 11, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Aug 11, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Feb 25, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Belgium
- Website
- lakefrontbio.com
News
- Bank Of America Crosses Below Threshold Of 10% Of Lakefront's Voting Rights, Transparency Notification Shows
- This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
- Crude Oil Gains 1%; Cintas Earnings Top Views
- TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
- This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
- RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45
- Bank Of America Raises Lakefront Biotherapeutics Stake Above To 10.11%
- Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26
- RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26
- Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate
Your note
Sign in to keep a note on LKFT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gilead Sciences Inc | 25.35% | 16,707,477 | 539.32M | Jun 29, 2026 |
| Tang Capital Management, LLC | 5.75% | 3,785,991 | 122.21M | Jun 29, 2026 |
| Madison Avenue Partners, LP | 5.23% | 3,447,807 | 111.30M | Jun 29, 2026 |
| Prosight Management, Lp | 3.10% | 2,043,344 | 65.96M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 2.53% | 1,667,119 | 53.81M | Jun 29, 2026 |
| Ameriprise Financial, Inc. | 1.93% | 1,272,249 | 41.07M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Columbia Funds Series Trust-Columbia Overseas Value Fund | 0.90% | 595,589 | 19.23M | Aug 30, 2026 |
| Columbia Fd.s Varbl Series TRT II-Columbia Varbl PORT. - Overseas Core | 0.43% | 280,317 | 9.05M | Jun 29, 2026 |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 0.12% | 80,031 | 2.58M | Aug 30, 2026 |
| American Century ETF Trust-Avantis International Equity ETF | 0.05% | 30,449 | 982.89K | Sep 29, 2026 |
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.03% | 16,569 | 534.85K | Jul 30, 2026 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.03% | 19,649 | 634.27K | Aug 30, 2026 |